ABHD18

Across TCGA pan-cancer cohorts, ABHD18 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ABHD18 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ABHD18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ABHD18 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BRCA, KIRC, and HNSC are the cancer types where ABHD18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.211	0.924	<.001	36	view →
KIRC	DFS	Median	III,IV	0.054	0.750	<.001	24	view →
HNSC	OS	Median	All	0.505	0.768	.004	12	view →
BLCA	DFS	Median	IV	1.000	0.195	.040	2	view →
UCEC	DFS	Median	All	1.000	0.632	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ABHD18–BRCA (OS)

Open the BRCA breakdown →